Achieve Life Sciences, Inc.
NASDAQ:ACHVBiotechnology
-$0.38 today
- Market cap
- $697.68M
- Beta
- 2.26
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.97
Volume 1.09M
Average 1.44M
ACHV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Achieve Life Sciences, Inc.NASDAQ: ACHV
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$9.84M, compared with -$12.58M a year earlier. Trailing-twelve-month EBITDA was -$50.86M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -43.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.84M+31.5% QoQ
- Last fiscal yearDec 2025
- -$53.6M-43.2% YoY
- LTMMar 2026
- -$50.86M-14.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.8% | +100.0% | +78.2 pp |
| 1 year | -43.2% | +100.0% | +143.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (53.6M) USD
- Year-over-year change
- -43.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (53.6M) | -43.2% |
| FY2024 | 2024-12-31 | (37.42M) | -40.0% |
| FY2023 | 2023-12-31 | (26.73M) | +33.7% |
| FY2022 | 2022-12-31 | (40.33M) | -22.6% |
| FY2021 | 2021-12-31 | (32.9M) | — |
EBITDA vs competitors
How ACHV compares with its peers on the latest reported figures
No competitor EBITDA figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 229K | 228K |
| Gross Profit | 0 | 0 | 0 | (229K) | (228K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.97M | 30.08M | 15.81M | 22.82M | 22.96M |
| Selling, General & Admin | 9.13M | 10.72M | 11.44M | 16.25M | 31.87M |
| Operating Expenses | 33.09M | 40.8M | 27.25M | 38.84M | 54.65M |
| Depreciation & Amortization | 250K | 236K | 228K | 229K | 228K |
| EBITDA | (32.9M) | (40.33M) | (26.73M) | (37.42M) | (53.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (33.09M) | (40.8M) | (27.25M) | (39.07M) | (54.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17K | 199K | 825K | 2.36M | 1.5M |
| Interest Expense | 0 | 1.79M | 2.85M | 2.18M | 819K |
| Other Income / Expenses | (58K) | (1.55M) | (2.57M) | (758K) | 232K |
| Income Before Tax | (33.15M) | (42.35M) | (29.82M) | (39.83M) | (54.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.15M) | (42.35M) | (29.82M) | (39.83M) | (54.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.05) | (3.95) | (1.50) | (1.24) | (1.25) |
| EPS (Diluted) | (4.05) | (3.95) | (1.50) | (1.24) | (1.25) |
| Weighted Avg Shares | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M |
| Weighted Avg Shares (Diluted) | 8.12M | 10.59M | 19.83M | 32.07M | 43.59M |
Achieve Life Sciences, Inc.
NASDAQ:ACHV
Intrinsic Alpha fair value
Locked
Current Price
$6.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.